Explore peer-reviewed studies on antimicrobial resistance, sterilization protocols, and outbreak management
Explore the groundbreaking phase I study of IMGN632, a novel CD123-targeting antibody-drug conjugate showing promise for relapsed/refractory acute myeloid leukemia.